Vabret); Clermont-Ferrand (Dr C. Henquell, Dr A. Mirand) ,
Avettand-Fenoel); Paris-Pitié-Salpêtrière Wirden); Paris Saint-Antoine (Dr L. Morand-Joubert), Dr M.L. Chaix ,
Chaillon); Versailles (Dr S. Marque-Juillet); Villejuif (Pr A.M. Roque-Afonso, Dr S. Haïm-Boukobza), INSERM UMR-S1136 (Dr P. Flandre, M. Grudé, Dr L. Assoumou, Dr D. Costagliola). The lead author for the ANRS AC11 Study Group is Dr Diane Descamps ,
CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and Disease, Annual Review of Immunology, vol.17, issue.1, pp.657-700, 1999. ,
DOI : 10.1146/annurev.immunol.17.1.657
Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity, Antimicrobial Agents and Chemotherapy, vol.49, issue.11, pp.4721-4732, 2005. ,
DOI : 10.1128/AAC.49.11.4721-4732.2005
Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir, Journal of Virology, vol.80, issue.10, pp.4909-4920, 2006. ,
DOI : 10.1128/JVI.80.10.4909-4920.2006
Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism, Antimicrobial Agents and Chemotherapy, vol.51, issue.2, pp.566-575, 2007. ,
DOI : 10.1128/AAC.00853-06
Current tests to evaluate HIV-1 coreceptor tropism, Current Opinion in HIV and AIDS, vol.4, issue.2, pp.136-142, 2009. ,
DOI : 10.1097/COH.0b013e328322f973
Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism, AIDS, vol.22, issue.14, pp.11-16, 2008. ,
DOI : 10.1097/QAD.0b013e32830ebcd4
Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients, Journal of Infectious Diseases, vol.203, issue.2, pp.237-245, 2011. ,
DOI : 10.1093/infdis/jiq030
A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients, PLoS ONE, vol.7, issue.9, p.23029482, 2012. ,
DOI : 10.1371/journal.pone.0046334.s004
Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism, Antimicrobial Agents and Chemotherapy, vol.55, issue.6, pp.2831-2836, 2011. ,
DOI : 10.1128/AAC.00091-11
URL : https://hal.archives-ouvertes.fr/hal-00675722
Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism, Antimicrobial Agents and Chemotherapy, vol.58, issue.4, pp.2167-2185, 2014. ,
DOI : 10.1128/AAC.02710-13
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023761
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution, J Virol, vol.66, pp.6777-6780, 1992. ,
Bioinformatics prediction of HIV coreceptor usage, Nature Biotechnology, vol.12, issue.12, pp.1407-1410, 2007. ,
DOI : 10.1007/s00894-003-0154-9
Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis, BMC Medical Informatics and Decision Making, vol.2009, issue.1, p.21569501, 2011. ,
DOI : 10.1097/QAD.0b013e32833e6cfb
Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study, Antimicrobial Agents and Chemotherapy, vol.54, issue.8, pp.3335-3340, 2010. ,
DOI : 10.1128/AAC.00148-10
URL : https://hal.archives-ouvertes.fr/hal-00594694
Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing, Hepatology, vol.54, issue.Suppl 1, pp.890-901, 2013. ,
DOI : 10.1002/hep.26383
URL : https://hal.archives-ouvertes.fr/inserm-00936562
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment, Journal of Antimicrobial Chemotherapy, vol.66, issue.2, pp.265-272, 2011. ,
DOI : 10.1093/jac/dkq458
Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists, AIDS Rev, vol.14, pp.208-217, 2012. ,
An SNP map of the human genome generated by reduced representation shotgun sequencing, Nature, vol.407, pp.513-516, 2000. ,
Population-Based Sequencing of the V3 Region of env for Predicting the Coreceptor Usage of Human Immunodeficiency Virus Type 1 Quasispecies, Journal of Clinical Microbiology, vol.45, issue.5, pp.1572-1580, 2007. ,
DOI : 10.1128/JCM.02090-06
Deep V3 Sequencing for HIV Type 1 Tropism in Treatment-Naive Patients: A Reanalysis of the MERIT Trial of Maraviroc, Clinical Infectious Diseases, vol.53, issue.7, pp.732-742, 2011. ,
DOI : 10.1093/cid/cir493
A permutation test sensitive to differences in areas for comparing ROC curves from a paired design, Statistics in Medicine, vol.56, issue.18, pp.2873-2893, 2005. ,
DOI : 10.1002/sim.2149
pROC: an open-source package for R and S+ to analyze and compare ROC curves, BMC Bioinformatics, vol.12, issue.1, p.77, 2011. ,
DOI : 10.1007/s00134-009-1641-y
Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients, Journal of Infectious Diseases, vol.203, issue.2, pp.237-245, 2011. ,
DOI : 10.1093/infdis/jiq030
Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage, Bioinformatics, vol.29, issue.4, pp.451-460, 2013. ,
DOI : 10.1093/bioinformatics/btt002